USE OF THE PHARMACEUTICAL CARE PROGRAM IN THE MANAGEMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS IN DHULE CIVIL HOSPITAL
Abstract
Aim & Objective: The study was planned to evaluate the effectiveness of pharmaceutical care on the control of medical parameters, such as Fasting plasma glucose, Glycosylated hemoglobin (HbA1c) and BMI also to evaluate drug therapy problems in patients with type 2 diabetes mellitus. Setting: the study was conducted at SBHGM College, Civil Hospital in Dhule MS.
Research design and Methods: A prospective, Open label and randomized control study was conducted with 200 type 2 diabetes patients with glycosylated haemoglobin of higher than 7.5%, they were divided into two groups: (I) control group without pharmaceutical care program (n=100), and (II) pharmaceutical care program (intervention) group (n=100).They were monitored for 3 consecutive visits. Patients in the control group received usual medical care, but patients in the intervention group received both standard medical care and pharmaceutical care.
Results: At the end of the study, a statistically significant fall was observed in the glycemic levels, BMI of patients in the intervention group as a small reduction, which is statistically not significant, was observed in the control group. Additionally, the follow-up of the intervention group by a pharmacist contributed to the resolution of 118 drug therapy problems identified.
Conclusion: pharmaceutical care program provide by pharmacist to patients with type 2 diabetes mellitus can give up measurable improvements in the glycemic control, BMI & resolute of drug therapy problems and improvements in the adherence to antidiabetic medication.
Keywords: Type 2 Diabetes mellitus, Pharmaceutical care program, and Fasting plasma glucose, Glycosylated hemoglobin (HbA1c) and Body mass index (BMI).
DOI
https://doi.org/10.22270/jddt.v8i5-s.1960References
International Diabetes Federation. Diabetes Atlas. 4th ed. Brussels; 2010; 100 p. 71-73
World Health Organization. "Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus". Retrieved 29 May 2007.
Matzer S, Leiter L, Daneman D, Gerstein H, Lau D, Ludwig S,et al. Clinical practice guidelines for the management of diabetes in Canada. CMAJ. 1998; 159:1–29.
American Diabetes Association: Implications of the diabetes control and complications trial. Diabetes Care 2002; 25:25–27.
Diabetes care, net.
Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990; 47(3):533–543.
Abuissa H, Bel DS, O’Keefe JH Jr. Strategies to prevent type 2 diabetes. Curr Med Res Opin. 2005; 21:1107–14.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin- dependent diabetes mellitus. N Engl J Med 1993; (329):977-986.
United kingdom Prospective Diabetes Study Group. Intensive blood – glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes mellitus (UKPDS 33). Lancet 1998; (352):837-853.
Cipolle RJ, Strand LM, Marley PC. Pharmaceutical care practice. New York:McGraw-Hills; 1998. p. 1110.
Dinesh KU et - Evaluation of the Impact of a Pharmaceutical Care Program for Diabetes Patients in Nepal: A Preliminary Study Indian Journal of Pharmacy Practice 2011; 4(4).
Cranor CW, Christensen DB. The Asheville Project: short-term outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash). 2003; 43(2):149–159.
HepKe, K.L., Martus, M.T., & Share, D.A. Costs and utilization associated with pharmaceutical adherence in a diabetic population. The AJMC; 10:144-151.
Coast-Senior EA, Kroner BA, Kelley CL, Trilli LE. Management of patient with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother. 1998; 32:636–41.
Anaya JP, Rivera JO, Lawson K, Garcia J, Luna J Jr, Ortiz M. Evaluation of pharmacist-managed diabetes mellitus under a collaborative drug therapy agreement. Am J Health Syst Pharm. 2008; 65:1841–5.
Rothman R, Malone R, Bryant B, Horlen C, Pignone M. Pharmacist led, primary care-based disease management improves hemoglobin HbA1c in high-risk patients with diabetes. Am J Med Qual. 2003; 18(2):51–8.
Suppapitiporn S, Chindavijak B, Onsanit S. Effect of diabetes drug counseling by pharmacist, diabetic disease booklet nd special medication containers on glycemic control of type 2 diabetes mellitus: a randomized controlled trial. Med Assoc Thai 2005; 88 Suppl 4:S134-41.
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of self-reported measure of medication adherence. Med Care. 1986; 24(1):67–74.
Published
Abstract Display: 379 
PDF Downloads: 650 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.